Authors: John Bartlett, Dennis Sgroi, Kai Treuner, et. al. Abstract: 505 Citation: J Clin Oncol 37, 2019 (suppl; abstr 505) Background: The aTTom study is a prospective phase III trial that randomized 6953 HR+ women to stop or continue tamoxifen (TAM) for 5 more years after completing at least 4 years of...
Pro zobrazení tohoto obsahu je třeba být přihlášen.